Medtronic has begun the final phase of separating MiniMed, its former diabetes technology company, after launching a share-exchange offer that allows shareholders to exchange Medtronic shares for shares in MiniMed representing up to 80.1% of the company’s shares. Medtronic currently owns 89.9% of MiniMed.
The offer represents the second part of a separation process that began when MiniMed went public in March 2026. The offer is scheduled to expire on October 9, 2026, with the shares available in the exchange offered at a 7% discount, according to the details in the article.
What will change between the two companies?
Geoff Martha, Medtronic’s chief executive officer, said the separation gives MiniMed greater focus and flexibility as an independent company, while allowing Medtronic to direct capital toward its cardiovascular, neuroscience, and surgical portfolios.
The agreement includes a provision allowing Medtronic to sell its entire remaining stake in MiniMed if demand for the offer exceeds the available shares. In that case, Medtronic could end its financial connection with the new company completely.
Kendall Au, an analyst at RBC Capital Markets, described the move as a procedural milestone in the separation process. She believes MiniMed’s exit aligns with Medtronic’s priorities, particularly because the diabetes technology business was spending on research and development at twice the rate of the rest of the company, according to her research note.
MiniMed after the separation
The transition to an independent company does not mean a change in the category MiniMed serves, according to Que Dallara, the company’s chief executive officer. But it gives the company full independence in allocating capital, setting its product roadmap, and making decisions quickly.
Since it began trading as an independent company, MiniMed said it had applied to the U.S. Food and Drug Administration for a review of its first insulin patch pump. It also completed enrollment of participants in a trial of an algorithm designed to calculate a person’s insulin needs without meal announcements.
These developments remain at the submission or testing stages; the article does not state that the patch pump has received regulatory approval, nor does it present the algorithm trial’s results.
certi.news analysis
The actual change here is more institutional and strategic than the launch of a new technology: MiniMed will have greater independence in funding and product-development decisions, while Medtronic gradually divests ownership of a business with high research and development intensity. This could allow the parent company to free up funds for areas such as cardiac ablation, renal denervation, the Altaviva nerve-stimulation system, and Hugo surgical robotics, the areas mentioned in RBC’s note.
For the technical reader, the significance of the move lies in the possibility that MiniMed’s product-development speed and priorities may differ after the separation, but the source provides no timeline for new products or details about the process’s effect on customers, prices, or availability. MiniMed’s stock rose about 18% from its March listing to $21.50 on Monday, but that figure reflects the stock’s performance and does not prove the success of products under development.